We are live on ! Find out more

Kazia Therapeutics

KZIA

Market cap $109M

7.00 USD

-1.08

13.37%

At close Updated Nov 5, 4:00 PM EST

1 day

-13.37%

5 days

-19.63%

1 month

-25.13%

3 months

-41.67%

6 months

-47.96%

Year to date

40%

1 year

-8.85%

5 years

-98.82%

10 years

-97.84%

About: Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Employees: 6

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 80%

Negative 0%

Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards

Recognition Highlights Kazia's Focus on Overcoming Treatment Resistance in Cancer SYDNEY, Nov. 5, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, has been named "Drug Discovery Company of the Year" in the 2026 BioTech Breakthrough Awards program, recognizing the Company's innovative approach to developing next-generation cancer therapeutics. "Treatment resistance remains one of the greatest challenges in advanced breast cancer and other difficult-to-treat cancers.

Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards

Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium

Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming Activity SYDNEY, Nov. 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that two abstracts highlighting new preclinical and translational research on paxalisib's differentiated biological activity and potential application across breast cancer settings have been accepted for poster presentation at this year's San Antonio Breast Cancer Symposium ("SABCS"), taking place on Dec. 8 through 11, 2026, in San Antonio, Texas. The presentations will explore two complementary areas of research: the distinct tumor and immune reprogramming effects of paxalisib compared with other dual PI3K/mTOR inhibitors in preclinical models, and its potential to suppress local recurrence and metastatic progression when administered following standard neoadjuvant chemo-immunotherapy in a preclinical model of stage III triple-negative breast cancer (TNBC): Poster 1 (P4-9-18): "Paxalisib uniquely induces durable tumour and immune reprogramming across breast cancer subtypes, challenging the paradigm that dual PI3K/mTOR inhibitors are biologically equivalent" Poster 2 (P4-10-26): "Suppression of Local and Metastatic Recurrence by Adjuvant PI3K/mTOR Inhibition Through Durable Immune Epigenetic Rewiring Following Neoadjuvant Chemo-Immunotherapy in Stage III Triple-Negative Breast Cancer" The research further explores paxalisib's differentiated ability to reprogram tumor and immune biology in preclinical models, suggesting that these effects are not necessarily shared by other dual PI3K/mTOR inhibitors.

Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium

This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference

SYDNEY, Oct. 29, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that John Friend, MD, Chief Executive Officer, and Jeffrey Kraws, Head of Corporate Strategy & Development, will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, being held November 9 to 11, 2026, in Boston, Massachusetts. Conference Details Event: Guggenheim 3rd Annual Healthcare Innovation Conference Date: Monday, November 9, 2026 Time: 8:30 a.m.

Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that Sovargen Co., Ltd.

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept. 9, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that the first patient has been dosed in Arm A of PNOC035, a Phase 2 platform study evaluating paxalisib in combination with gemcitabine for patients ages 1 to 39 with recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT).

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript

Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript

Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Paxalisib Into a Phase 2 Clinical Study to Evaluate Paxalisib in Immunotherapy-Resistant MSS/pMMR Colorectal Cancer SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new preclinical and translational data showing that its lead asset, paxalisib, reduced tumor burden, the total amount of cancer in the body, by 52% (p=0.035) in microsatellite stable (MSS) / proficient mismatch repair (pMMR) colorectal cancer.

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expected By Year-End 2026 and Full Enrollment by End of 2027 SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new preclinical data demonstrating the safety and anti-tumor activity of paxalisib in HR+/HER2- breast cancer, including evidence that paxalisib resensitized CDK4/6 inhibitor-resistant tumors to standard-of-care therapy.

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Aug. 31, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the closing of its previously announced oversubscribed, tranched registered public offering (the "Offering") generating approximately $40 million in upfront gross proceeds. Both clinical milestone-linked warrant tranches were priced at premiums to the $15.50 offering price, with exercise prices of $17.825 per ADS, a 15% premium, tied to the Company's Stage IV triple-negative breast cancer ("TNBC") data readout, and $19.375 per ADS, a 25% premium, tied to the Company's HR+/HER2- breast cancer data readout.

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

See News Rankings

Price charts implemented using Lightweight Charts™